Navigation Links
Chemotherapy effective for patients with resected SCLC or large-cell neuroendocrine carcinoma
Date:6/15/2012

DENVER Research presented in the July 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concluded that patients with limited large cell neuroendocrine tumors or with limited stage small-cell lung cancer who were treated with perioperative chemotherapy and surgery had better overall survival outcomes than patients treated with surgery alone.

Small-cell lung cancer (SCLC) represents about 15 percent of lung cancers annually. Of those, about 30 percent of patients have limited disease SCLC. Whereas large-cell neuroendocrine carcinoma (LCNEC) is a subgroup of large-cell carcinoma, that has characteristics similar to SCLC. Surgery in these groups of patients are rare and researchers wanted to know if perioperative chemotherapy would benefit the patients.

The retrospective study looked at 74 patients who underwent lung cancer surgery at the Surgical Centre Marie Lannelongue in Le Plessis Robinson, France between 1979 and 2007. Forty-five patients underwent surgery combined with perioperative chemotherapy and 29 underwent surgery alone. They found, "treatment involving surgery plus perioperative chemotherapy was associated with a significantly longer OS (overall survival) than surgery alone (6.1 years and 2.3 years, respectively)."

The authors point out that there were limitations to their study. Because the data was from 1979, the previous staging system was used. The authors also point out that, "more patients had a node involvement in the chemotherapy group, indicating that physicians may have offered chemotherapy to patients with more advanced disease." However, no conclusion could be made because of the, "small population examined in this study, its retrospective nature, the difference in follow-up between the two groups and the heterogeneity of the combined treatments."

The authors point out that due to the rarity of this population, a prospective trial is unlikely to be feasible and these retrospective data may be of value.


'/>"/>

Contact: Kristal Griffith
Kristal.Griffith@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
2. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
3. Genetic predictor of breast cancer response to chemotherapy
4. Chemotherapys effect on overall survival seems to increase based on tumor size
5. Accelerated chemotherapy given before surgery benefits patients with muscle-invasive bladder cancer
6. Breast MRI helps predict chemotherapys effectiveness
7. Why chemotherapy fails
8. Overexpression of proteins 14-3-3 related to chemotherapy resistance
9. HIV Prevention Pill Cost-Effective for High-Risk Men: Study
10. Pig stomach mucins are effective as anti-viral agents for consumer products
11. Lower-Dose Radioiodine Effective Against Thyroid Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2020)... ... February 19, 2020 , ... ... and application deadline for its new Lifestyle Medicine Residency Curriculum (LMRC). The curriculum ... implementation into medical residency programs. Driven by resident involvement, the curriculum has ...
(Date:2/19/2020)... BOSTON (PRWEB) , ... February 19, 2020 , ... ... , MedTech Start Up Founders Encouraged to Apply to Participate in 2020 Cohort ... the MedTech IGNITE program is now accepting applications from startup founders ...
(Date:2/19/2020)... , ... February 19, 2020 , ... ... and consistency of healthcare delivery, announced that it will participate in the ... Orlando, Florida. BPM+ Health will engage healthcare professionals and other stakeholders at HIMSS20 ...
(Date:2/19/2020)... ... February 19, 2020 , ... SEAL SHIELD, LLC - ... result of healthcare-acquired infections (HAIs.) According to The Centers for Disease Control (CDC), 80% ... large amount of screens that are now acting as an extension of people’s hands, ...
(Date:2/16/2020)... ... February 16, 2020 , ... Accumen Inc., the leader in ... and The Joint Commission to provide a complimentary series of Patient Blood Management ... and transfusion safety officers) within U.S. hospitals. , “Accumen’s mission is ...
Breaking Medicine News(10 mins):
(Date:2/26/2020)... ... February 26, 2020 , ... Anchora Medical ... of a $4.5 million financing round led by HOYA Corporation (“HOYA”) (ADR: HOCPY, ... used to complete Anchora's family of single-use laparoscopic suturing devices. , HOYA, a ...
(Date:2/23/2020)... ... February 23, 2020 , ... ... International, the Commission on Accreditation of Rehabilitation Facilities. CARF International is an ... promote quality, value, and optimal outcomes through continuous improvements under their consultative ...
(Date:2/23/2020)... ... February 23, 2020 , ... ... an examination of the complex interplay between the brain, central nervous system and ... time at the International Association of Eating Disorders Professionals (iaedp™) 2020 Symposium in ...
Breaking Medicine Technology: